AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 8 - (NewsRx.com & NewsRx.net) --
VaxGen, Inc. (VXGN) presented laboratory data at an international scientific conference indicating that antibodies to HIV subtype C (HIV-C) have an unexpected ability to bind to significant regions of another HIV subtype.
The findings indicate that a vaccine that induces HIV-C antibodies may be effective at preventing infection not only by HIV-C but by other subtypes as well. HIV-C causes half of the world's HIV infections and is the predominant subtype in southern Africa, India, and China. VaxGen also described a new trivalent formulation of its vaccine, AIDSVAX, which is designed to prevent infection by three of the world's five major HIV subtypes, including HIV-C. The development of this formulation, which has yet to be tested in human clinical trials, furthers the company's goal of tailoring vaccines to target specific HIV subtypes and strains in various geographic regions.
"We found that antibodies to HIV-C bind well to a functionally significant site on the C subtype and to the same site on the B subtype," said Phillip Berman, PhD, VaxGen. "In contrast, antibodies to HIV-B did not bind nearly as well to the same region on HIV-C. These findings are from animal studies and need to be confirmed in humans, but they suggest that a vaccine directed against HIV-C may be able to protect against a broader range of different HIV subtypes than other ...
Source: HighBeam Research, Vaccine For Developing World Shows Unexpected Activity.(Brief Article)